Back to top

Image: Bigstock

Zoetis Inc.

Read MoreHide Full Article

Zoetis’ expects to see stronger growth from its companion animal portfolio in 2017 driven by its dermatology portfolio, Apoquel and Cytopoint, further penetration of Simparica, and ongoing uptake of new vaccines.Shares of Zoetis have outperformed the industry in the past one year. However, Zoetis lowered its guidance for 2017 concurrent with its fourth-quarter results. Management expects revenue growth to be negatively impacted from product rationalization, especially in the first two quarters of the year. Surgical fluid products continued to decline in 2016 while performance of Zoetis’ livestock business has been disappointing. Other headwinds include disease outbreaks and stiff competition in the animal health space. Disease outbreak among animals is a major concern for Zoetis’ livestock products. Estimates for 2017 have come down slightly in the last 30 days.


In-Depth Zacks Research for the Tickers Above


Normally $25 each - click below to receive one report FREE:


Zoetis Inc. (ZTS) - free report >>

Published in